Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 538-541

  Trives, Mehdi Ziadi ^a   Llácer, José María Bonete ^b   Escudero, Miguel Alfonso García ^c   Pastor, Carlos Jeremías Martínez ^c  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c Mental Health Unit   (Spain)

Author keywords

aripiprazole; hyperprolactinemia; risperidone; schizophrenia

Indexed keywords

ARIPIPRAZOLE; PALIPERIDONE; PROLACTIN; RISPERIDONE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPROLACTINEMIA; INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROLACTIN; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879842119     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182970431     Document Type: Article

References (31)

1. Horseman ND. Prolactin. In: deGroot L, Jamenson J, eds. Endocrinology. Philadelphia, PA: WB Saunders; 2001:209-220.
2. Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. J Urol. 1989;142(4):992-994.
3. Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(suppl 2):S108-S114.
4. Bebbington PE, Angermeyer M, Azorin JM, et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl. 2009;(438):22-28.
5. Montejo AL, Majadas S. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med. 2010;7(10):3404-3413.
6. Falgia G. In: DeGroot L, Jamenson J, eds. Endocrinology. Philadelphia, PA: WB Saunders; 2001:242-329.
7. Cooke NE. Prolactin: basic physiology. In: deGroot L, Jamenson J, eds. Endocrinology. Philadelphia, PA: WB Saunders; 1994:368-393.
8. Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32:315-326.
9. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21(7):768-773.
10. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302(3):1129-1234.
11. Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr Bull. 2004;30(4):767-779.
12. Freeman B, Levy W, Gorman JM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J Psychiatr Pract. 2007;13(2):120-124.
13. Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol. 2006;16(3):317-326.
14. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411.
15. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649-666.
16. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD004578.
17. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother. 2002;3(10):1381-1391.
18. Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639-661.
19. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9):763-771.
20. Hanssens L, L'Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95.
21. Montejo AL, García M, Espada M, et al. Propiedades psicométricas del cuestionario de disfunción sexual secuandaria a fármacos. Actas Esp Psiquiatr. 2000;28(3):141-150.
22. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-912.
23. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980;303(26):1511-1514.
24. Tworoger SS, Eliassen AH, Sluss P, et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482-1488.
25. Bushe CJ, Bradley AJ, Wildgust HJ, et al. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res. 2009;114(1-3):6-16.
26. Harvey PW, Everett DJ. Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health. Best Pract Res Clin Endocrinol Metab. 2006;20(1): 145-165.
27. Harvey PW, Everett D, Springall C. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol. 2006;25(7):395-404.
28. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol. 2008;22(2 suppl):20-27.
29. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-977.
30. Hoffer ZS, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorigenic hyperprolactinemia. Psychosomatics. 2009;50(4):317-324.
31. Montejo AL, Riesgo Y, Luque J, et al. Observational, open-label, prospective multicentre study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr. 2010;38(1):13-21.